Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity
Open Access
- 1 August 2019
- journal article
- research article
- Published by Elsevier in Cell Reports
- Vol. 28 (9) , 2345-2357.e5
Abstract
No abstract availableKeywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- European Research Council
This publication has 46 references indexed in Scilit:
- RNA‐Peptide nanoplexes drug DNA damage pathways in high‐grade serous ovarian tumorsBioengineering & Translational Medicine, 2018
- Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Annals of Oncology, 2017
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2010
- Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage responseMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- Chromatin modulation and the DNA damage responseExperimental Cell Research, 2006
- Inhibition of Centrosome Separation after DNA Damage: A Role for Nek2Radiation Research, 2004
- The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent CisplatinJournal of Biological Chemistry, 2000